EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

NT ‐ proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring

Charlotte Durrington iD, Christian Battersby, Laura Holt, Alexandra Fairman, Scarlett Strickland, Thomas Salisbury, Helena A Turton, Lisa Watson, Ian Smith, Stefan Roman, Jenna Ablott iD, Felicity Hitchcock and 18 more

Respirology · 2025

DOI: 10.1111/resp.70087 ↗

At a glance

Beobachtungsstudie in Respirology, 2025. Written by Charlotte Durrington and 29 co-authors. Institution: Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Major MEDLINE topics: Hypertension, Pulmonary, Natriuretic Peptide, Brain, Peptide Fragments, Point-of-Care Systems. Cited 6 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, Janssen UK.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Objectives Brain natriuretic peptide (BNP) and N‐terminal prohormone of BNP (NT‐proBNP) are important biomarkers in pulmonary arterial hypertension (PAH). However, results are rarely available at the time of clinical assessment. The reliability of NT‐proBNP/BNP point‐of‐care tests (POCT) in PAH patients and the stability of NT‐proBNP in posted blood samples, to simulate remote monitoring, was investigated.

Methods

Group 1 PAH patients were prospectively recruited. A sample of 40 was required to demonstrate an intraclass correlation coefficient (ICC) of 0.94 with a 95% confidence interval width of < 0.1 for agreement between POCT and the laboratory standard. Blood samples were taken at two time‐points for laboratory and POCT NT‐proBNP/BNP. Separate samples were returned to the laboratory by post and some samples were assessed pre‐ and post‐exercise assessing the impact of exercise.

Results

Forty‐one patients were enrolled with 56 study visits. NT‐proBNP laboratory and POCT ( n = 50) provided equivalent test results (Passing–Bablok slope = 1.08, CI = 0.97–1.19, intercept = 18.22, CI = −41.6 to 4.5) and ICC = 0.97. However, laboratory and POCT BNP ( n = 49), showed non‐equivalence (Passing–Bablok slope = 1.24, CI 1.11–1.31, intercept = −5.11, CI = −9.4 to −0.46), ICC = 0.96. POCT NT‐proBNP/BNP correctly classified 92% and 86% of cases, respectively against COMPERA 2.0 4‐risk‐strata thresholds. NT‐proBNP postal laboratory samples and immediately processed NT‐proBNP laboratory samples showed good agreement and exercise had no clinically significant effect on NT‐proBNP/BNP results. Laboratory BNP identified fewer patients as high risk compared to NT‐proBNP. BNP and NT‐proBNP risk status agreed at only 57% of visits ( p < 0.0009).

Conclusions

These data support the use of POCT NT‐proBNP as a rapidly accessible and reliable alternative in clinical settings and highlight the potential of NT‐proBNP for remote monitoring via posted samples. Trial Registration ClinicalTrials.gov registration: NCT05421949 image

Subjects

MeSH terms (MEDLINE)

Hypertension, PulmonaryNatriuretic Peptide, BrainPeptide FragmentsPoint-of-Care SystemsPoint-of-Care TestingPulmonary Arterial HypertensionAdultAgedFemaleHumansMaleMiddle AgedBiomarkersProspective StudiesReproducibility of Results

Author keywords

natriuretic peptidespoint‐of‐care testingpulmonary hypertension

Substances

BiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Authors and institutions

  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
  • Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • National Institute for Health and Care Research Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals, Sheffield, UK.
  • Clinical Biochemistry, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Clinical Chemistry, Barnsley Hospital NHS Foundation Trust, Barnsley, UK.
  • National Heart and Lung Institute, Imperial College London, London, UK.

ORCID profiles: Charlotte Durrington, Jenna Ablott, Robin Condliffe, A A Roger Thompson

Funding

  • Wellcome Trust
  • Janssen UK

Cite

APA

Durrington, C., Battersby, C., Holt, L., Fairman, A., Strickland, S., Salisbury, T., Turton, H. A., Watson, L., Smith, I., Roman, S., Ablott, J., Hitchcock, F., Roddis, C., Oakes, E., Wilshaw, H., Woodrow, I., Armstrong, I., Charalampopoulos, A., Elliot, C. A., …, & Thompson, A. A. R. (2025). NT ‐ proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring. Respirology. https://doi.org/10.1111/resp.70087

Vancouver

Durrington C, Battersby C, Holt L, Fairman A, Strickland S, Salisbury T, et al. NT ‐ proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring. Respirology. 2025. doi:10.1111/resp.70087

BibTeX
@article{Durrington2025,
  author = {Durrington, Charlotte and Battersby, Christian and Holt, Laura and Fairman, Alexandra and Strickland, Scarlett and Salisbury, Thomas and Turton, Helena A and Watson, Lisa and Smith, Ian and Roman, Stefan and Ablott, Jenna and Hitchcock, Felicity and Roddis, Chloe and Oakes, Eleanor and Wilshaw, Heather and Woodrow, Iain and Armstrong, Iain and Charalampopoulos, Athanasios and Elliot, Charlie A and Hameed, Abdul and Hamilton, Neil and Hurdman, Judith A and Lawrie, Allan and Middleton, Jennifer T and Zafar, Hamza and Rothman, Alex M K and Condliffe, Robin and Lewis, Robert A and Kiely, David G and Thompson, A A Roger},
  title = {NT ‐ proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring},
  journal = {Respirology},
  year = {2025},
  doi = {10.1111/resp.70087}
}
Start for free →